靶向结直肠癌人表皮生长因子受体2(HER2)癌基因
本文综述HER2扩增作为结直肠癌(CRC)致癌驱动因素、预后与预测生物标志物及可操作治疗靶点的作用,并讨论该瘤种HER2检测的特殊性。尽管HER2在CRC中的预后价值尚不明确,其治疗靶点地位已确立,独立研究显示生物标志物驱动的HER2靶向治疗在缓解率和缓解持续时间上带来显著临床获益,可与免疫治疗及其他精准肿瘤学范例相媲美。
要点
- 约5%转移性CRC由HER2扩增或突变驱动。
- HER2作为CRC预后标志物的作用尚不确定。
- HER2靶向治疗在部分转移性CRC中显示显著临床获益。
核心结论
- HER2作为CRC治疗靶点的地位已确立,靶向策略有望改变部分转移性CRC患者的治疗范式。
研究设计与样本
- 本文为综述,基于患者来源异种移植的功能与基因组分析及独立研究,讨论HER2在CRC中的作用与检测特殊性。
主要发现
- 约5%转移性CRC肿瘤由HER2扩增或突变驱动。
- HER2作为CRC预后生物标志物的作用仍不确定。
- 独立研究记录生物标志物驱动的HER2靶向治疗在缓解率和缓解持续时间上带来显著临床获益,与免疫治疗及其他精准肿瘤学范例相比具有优势。
临床怎么用
- 对转移性CRC可考虑HER2检测以筛选生物标志物驱动的HER2靶向治疗获益人群。
局限性
- HER2在CRC中的预后价值尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric cancers. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic colorectal cancer (CRC) tumors is driven by amplification or mutation of HER2. This paper reviews the role of HER2 amplification as an oncogenic driver, a prognostic and predictive biomarker, and a clinically actionable target in CRC, considering the specifics of HER2 testing in this tumor type. While the role of HER2 as a biomarker for prognosis in CRC remains uncertain, its relevance as a therapeutic target has been established. Indeed, independent studies documented substantial clinical benefit in patients treated with biomarker-driven HER2-targeted therapies, with an impact on response rates and duration of response that compared favorably with immunotherapy and other examples of precision oncology. HER2-targeted therapeutic strategies have the potential to change the treatment paradigm for a clinically relevant subgroup of metastatic CRC patients.
引用
- Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018. PMID: 29659677. doi:10.1093/annonc/mdy100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。